公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
公司地址 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
電話號碼 +1 617 621-7722
傳真號碼 +1 617 494-0480
公司網頁 https://www.ironwoodpharma.com
員工數量 100
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Tammi L. Gaskins Senior Vice President and Chief Commercial Officer 美元 474.72K 28/04/2026
Mr. Thomas A. McCourt Director and Chief Executive Officer 美元 867.57K 28/04/2026
Mr. Gregory S. Martini Senior Vice President and Chief Financial Officer 美元 470.47K 28/04/2026
Dr. Michael Shetzline, M.D.,PhD Senior Vice President, Chief Medical Officer and Head of Research and Drug Development -- 28/04/2026
Mr. John Minardo Senior Vice President, Chief Legal Officer and Secretary -- 28/04/2026
Mr. Ronald Silver, C.P.A. Principal Accounting Officer, Senior Vice President and Corporate Controller -- 26/02/2026
 
董事會成員
董事會 職務 更新日期
Dr. Alexander J. Denner, PhD Independent Director 28/04/2026
Mr. Jay P. Shepard Independent Director 28/04/2026
Dr. Mark G. Currie,PhD Independent Director 28/04/2026
Mr. Thomas A. McCourt Director and Chief Executive Officer 28/04/2026
Ms. Julie H. McHugh Chairman of the Board 28/04/2026
Ms. Catherine Moukheibir Independent Director 28/04/2026
Mr. Jon R. Duane Independent Director 28/04/2026
Ms. Marla L. Kessler Independent Director 28/04/2026
 
所屬ETF (更新日期: 02/05/2026 02:31)
代號 名稱 佔比% 持有日期
IBBQInvesco Nasdaq Biotechnology ETF0.01%29/04/2026
ITWOProShares Russell 2000 High Income ETF0.005%29/04/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.004%29/04/2026
URTYProShares UltraPro Russell20000.004%29/04/2026
BIBProShares Ultra Nasdaq Biotechnology0.004%29/04/2026
UWMProShares Ultra Russell20000.004%29/04/2026
FLQSFranklin US Small Cap Mltfctr Idx ETF0.003%29/04/2026
ACSGAmerican Century Small Cp Gr Insgts ETF0.002%29/04/2026
PBSMInvesco PureBeta MSCI USA Small Cap ETF0.0004%31/05/2023
HDGProShares Hedge Replication0.0001%29/04/2026
AVTMAvantis Total Equity Markets ETF0.00004%29/04/2026
RBProshares Russell 2000 Dynamic BufferETF0.00003%29/04/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%06/03/2026
DEEPAcquirers Small and Micro Deep Value ETF<0.000001%23/03/2026
EBITHarbor AlphaEdge Small Cap Earners ETF<0.000001%04/02/2026
ETHOEtho Climate Leadership US ETF<0.000001%09/04/2026
EWSCInvesco S&P SmallCap 600® Equal Wt ETF<0.000001%20/03/2023
FEACFidelity Enhanced U.S. All-Cap Eq ETF<0.000001%08/04/2026
IJRiShares Core S&P Small-Cap ETF<0.000001%06/03/2026
IJSiShares S&P Small-Cap 600 Value ETF<0.000001%06/03/2026
  1    2   3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.